Related Experiment Videos
The control of morphogenesis in Candida albicans
Journal of Dental Research
|March 1, 1984
Summary
N-acetylhexosamine derivatives induce Candida albicans morphogenesis without cellular uptake or supporting growth. 2-Deoxyglucose inhibits germ-tube formation intracellularly, with inhibition reversed by glucose.
Area of Science:
- Mycology
- Cell Biology
- Biochemistry
Background:
- Candida albicans is an opportunistic fungal pathogen.
- Morphogenesis, specifically germ-tube formation, is a critical virulence factor in C. albicans.
- Understanding the regulation of morphogenesis is crucial for developing antifungal strategies.
Purpose of the Study:
- To investigate the role of N-acetylhexosamine derivatives in inducing Candida albicans morphogenesis.
- To elucidate the mechanism of 2-deoxyglucose inhibition of germ-tube formation.
Main Methods:
- Induction of germ-tube formation using various N-acetylhexosamine derivatives.
- Growth assays to assess yeast viability and support.
- Inhibition studies with 2-deoxyglucose and its derivatives.
- Competitive inhibition assays with glucose to determine 2-deoxyglucose uptake mechanisms.
Main Results:
- N-acetylhexosamine derivatives, including N-acetylglucosamine-agarose, N-acetylmannosamine, hyaluronic acid, chitin, and mucin, gratuitously induced germ-tube formation.
- These inducers were not internalized by yeast cells and did not support growth.
- 2-Deoxyglucose potently inhibited germ-tube formation at 50 microM without affecting growth yield at 2.5 mM.
- Glucose competitively inhibited 2-deoxyglucose uptake, indicating intracellular action of 2-deoxyglucose.
Conclusions:
- Specific N-acetylhexosamine derivatives can trigger C. albicans morphogenesis independently of nutrient uptake.
- 2-Deoxyglucose acts intracellularly to inhibit germ-tube formation, suggesting a critical role for intracellular glucose metabolism or signaling in this process.
- These findings provide insights into the regulation of C. albicans morphogenesis and potential targets for antifungal therapies.